Litigation Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
| Docket | ⤷ Start Trial | Date Filed | 2017-09-06 |
| Court | District Court, D. New Jersey | Date Terminated | |
| Cause | 15:1126 Patent Infringement | Assigned To | Susan Davis Wigenton |
| Jury Demand | None | Referred To | Leda D. Wettre |
| Patents | 6,315,720; 6,561,977; 6,755,784; 7,189,740; 7,465,800; 7,855,217; 7,968,569; 8,315,886; 8,404,717; 8,530,498; 8,626,531; 8,648,095; 9,056,120; 9,101,621; 9,101,622 | ||
| Link to Docket | External link to docket | ||
Small Molecule Drugs cited in CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD.
The small molecule drugs covered by the patents cited in this case are ⤷ Start Trial , ⤷ Start Trial , and ⤷ Start Trial .
Details for CELGENE CORPORATION v. LOTUS PHARMACEUTICAL CO., LTD. (D.N.J. 2017)
| Date Filed | Document No. | Description | Snippet | Link To Document |
|---|---|---|---|---|
| 2017-09-06 | 90 | 1 The patents-in-suit cover United States Patent Nos. 5,635,517; 6,315,720 (“the ʼ720 patent”); 6,561,977…ʼ720 patent (Count II) 2; the ʼ977 patent (Count III); the ʼ784 patent (Count IV); the ʼ886 patent (Count…prior to the expiration of Celgene’s patents (collectively, “patents-in-suit”). 1 (Id. ¶¶ 1, 39.) …challenging the patent eligibility of Celgene’s Risk Evaluation and Mitigation Strategy patents (“REMS Patents…6,561,977 (“the ʼ977 patent”); 6,755,784 (“the ʼ784 patent”); 7,189,740; 7,465,800; 7,855,217; 7,968,569 | External link to document | |
| >Date Filed | >Document No. | >Description | >Snippet | >Link To Document |
